rs281864944

Variant summary

Our verdict is Pathogenic. The variant received 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong

The NM_000251.3(MSH2):​c.704_705delAA​(p.Lys235ArgfsTer20) variant causes a frameshift change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.00000206 in 1,459,814 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Pathogenic (★★★). Variant results in nonsense mediated mRNA decay.

Frequency

Genomes: not found (cov: 32)
Exomes 𝑓: 0.0000021 ( 0 hom. )

Consequence

MSH2
NM_000251.3 frameshift

Scores

Not classified

Clinical Significance

Pathogenic reviewed by expert panel P:8

Conservation

PhyloP100: 8.97

Publications

6 publications found
Variant links:
Genes affected
MSH2 (HGNC:7325): (mutS homolog 2) This locus is frequently mutated in hereditary nonpolyposis colon cancer (HNPCC). When cloned, it was discovered to be a human homolog of the E. coli mismatch repair gene mutS, consistent with the characteristic alterations in microsatellite sequences (RER+ phenotype) found in HNPCC. Two transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Apr 2012]
MSH2 Gene-Disease associations (from GenCC):
  • Lynch syndrome
    Inheritance: AD Classification: DEFINITIVE, SUPPORTIVE Submitted by: G2P, ClinGen, Orphanet
  • Lynch syndrome 1
    Inheritance: AD Classification: DEFINITIVE, STRONG Submitted by: Labcorp Genetics (formerly Invitae), Genomics England PanelApp, Ambry Genetics
  • Muir-Torre syndrome
    Inheritance: AD Classification: DEFINITIVE, STRONG, SUPPORTIVE Submitted by: Genomics England PanelApp, Orphanet, G2P
  • mismatch repair cancer syndrome 1
    Inheritance: AR Classification: DEFINITIVE, SUPPORTIVE Submitted by: ClinGen, Orphanet
  • mismatch repair cancer syndrome 2
    Inheritance: AR Classification: DEFINITIVE, STRONG Submitted by: Labcorp Genetics (formerly Invitae), G2P
  • ovarian cancer
    Inheritance: AD Classification: STRONG Submitted by: Genomics England PanelApp
  • malignant pancreatic neoplasm
    Inheritance: AD Classification: MODERATE Submitted by: Genomics England PanelApp
  • prostate cancer
    Inheritance: AD Classification: MODERATE Submitted by: Ambry Genetics
  • rhabdomyosarcoma
    Inheritance: AR Classification: MODERATE Submitted by: Genomics England PanelApp
  • breast cancer
    Inheritance: AD Classification: NO_KNOWN Submitted by: Ambry Genetics
  • hereditary breast carcinoma
    Inheritance: AD Classification: NO_KNOWN Submitted by: ClinGen

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Pathogenic. The variant received 18 ACMG points.

PVS1
Loss of function variant, product undergoes nonsense mediated mRNA decay. LoF is a known mechanism of disease.
PM2
Very rare variant in population databases, with high coverage;
PP5
Variant 2-47412469-CAA-C is Pathogenic according to our data. Variant chr2-47412469-CAA-C is described in CliVar as Pathogenic. Clinvar id is 91182.Status of the report is reviewed_by_expert_panel, 3 stars. Variant chr2-47412469-CAA-C is described in CliVar as Pathogenic. Clinvar id is 91182.Status of the report is reviewed_by_expert_panel, 3 stars. Variant chr2-47412469-CAA-C is described in CliVar as Pathogenic. Clinvar id is 91182.Status of the report is reviewed_by_expert_panel, 3 stars. Variant chr2-47412469-CAA-C is described in CliVar as Pathogenic. Clinvar id is 91182.Status of the report is reviewed_by_expert_panel, 3 stars. Variant chr2-47412469-CAA-C is described in CliVar as Pathogenic. Clinvar id is 91182.Status of the report is reviewed_by_expert_panel, 3 stars. Variant chr2-47412469-CAA-C is described in CliVar as Pathogenic. Clinvar id is 91182.Status of the report is reviewed_by_expert_panel, 3 stars. Variant chr2-47412469-CAA-C is described in CliVar as Pathogenic. Clinvar id is 91182.Status of the report is reviewed_by_expert_panel, 3 stars. Variant chr2-47412469-CAA-C is described in CliVar as Pathogenic. Clinvar id is 91182.Status of the report is reviewed_by_expert_panel, 3 stars. Variant chr2-47412469-CAA-C is described in CliVar as Pathogenic. Clinvar id is 91182.Status of the report is reviewed_by_expert_panel, 3 stars. Variant chr2-47412469-CAA-C is described in CliVar as Pathogenic. Clinvar id is 91182.Status of the report is reviewed_by_expert_panel, 3 stars. Variant chr2-47412469-CAA-C is described in CliVar as Pathogenic. Clinvar id is 91182.Status of the report is reviewed_by_expert_panel, 3 stars. Variant chr2-47412469-CAA-C is described in CliVar as Pathogenic. Clinvar id is 91182.Status of the report is reviewed_by_expert_panel, 3 stars. Variant chr2-47412469-CAA-C is described in CliVar as Pathogenic. Clinvar id is 91182.Status of the report is reviewed_by_expert_panel, 3 stars. Variant chr2-47412469-CAA-C is described in CliVar as Pathogenic. Clinvar id is 91182.Status of the report is reviewed_by_expert_panel, 3 stars. Variant chr2-47412469-CAA-C is described in CliVar as Pathogenic. Clinvar id is 91182.Status of the report is reviewed_by_expert_panel, 3 stars. Variant chr2-47412469-CAA-C is described in CliVar as Pathogenic. Clinvar id is 91182.Status of the report is reviewed_by_expert_panel, 3 stars. Variant chr2-47412469-CAA-C is described in CliVar as Pathogenic. Clinvar id is 91182.Status of the report is reviewed_by_expert_panel, 3 stars. Variant chr2-47412469-CAA-C is described in CliVar as Pathogenic. Clinvar id is 91182.Status of the report is reviewed_by_expert_panel, 3 stars. Variant chr2-47412469-CAA-C is described in CliVar as Pathogenic. Clinvar id is 91182.Status of the report is reviewed_by_expert_panel, 3 stars. Variant chr2-47412469-CAA-C is described in CliVar as Pathogenic. Clinvar id is 91182.Status of the report is reviewed_by_expert_panel, 3 stars. Variant chr2-47412469-CAA-C is described in CliVar as Pathogenic. Clinvar id is 91182.Status of the report is reviewed_by_expert_panel, 3 stars. Variant chr2-47412469-CAA-C is described in CliVar as Pathogenic. Clinvar id is 91182.Status of the report is reviewed_by_expert_panel, 3 stars. Variant chr2-47412469-CAA-C is described in CliVar as Pathogenic. Clinvar id is 91182.Status of the report is reviewed_by_expert_panel, 3 stars. Variant chr2-47412469-CAA-C is described in CliVar as Pathogenic. Clinvar id is 91182.Status of the report is reviewed_by_expert_panel, 3 stars. Variant chr2-47412469-CAA-C is described in CliVar as Pathogenic. Clinvar id is 91182.Status of the report is reviewed_by_expert_panel, 3 stars. Variant chr2-47412469-CAA-C is described in CliVar as Pathogenic. Clinvar id is 91182.Status of the report is reviewed_by_expert_panel, 3 stars. Variant chr2-47412469-CAA-C is described in CliVar as Pathogenic. Clinvar id is 91182.Status of the report is reviewed_by_expert_panel, 3 stars. Variant chr2-47412469-CAA-C is described in CliVar as Pathogenic. Clinvar id is 91182.Status of the report is reviewed_by_expert_panel, 3 stars. Variant chr2-47412469-CAA-C is described in CliVar as Pathogenic. Clinvar id is 91182.Status of the report is reviewed_by_expert_panel, 3 stars. Variant chr2-47412469-CAA-C is described in CliVar as Pathogenic. Clinvar id is 91182.Status of the report is reviewed_by_expert_panel, 3 stars. Variant chr2-47412469-CAA-C is described in CliVar as Pathogenic. Clinvar id is 91182.Status of the report is reviewed_by_expert_panel, 3 stars. Variant chr2-47412469-CAA-C is described in CliVar as Pathogenic. Clinvar id is 91182.Status of the report is reviewed_by_expert_panel, 3 stars. Variant chr2-47412469-CAA-C is described in CliVar as Pathogenic. Clinvar id is 91182.Status of the report is reviewed_by_expert_panel, 3 stars. Variant chr2-47412469-CAA-C is described in CliVar as Pathogenic. Clinvar id is 91182.Status of the report is reviewed_by_expert_panel, 3 stars. Variant chr2-47412469-CAA-C is described in CliVar as Pathogenic. Clinvar id is 91182.Status of the report is reviewed_by_expert_panel, 3 stars. Variant chr2-47412469-CAA-C is described in CliVar as Pathogenic. Clinvar id is 91182.Status of the report is reviewed_by_expert_panel, 3 stars. Variant chr2-47412469-CAA-C is described in CliVar as Pathogenic. Clinvar id is 91182.Status of the report is reviewed_by_expert_panel, 3 stars. Variant chr2-47412469-CAA-C is described in CliVar as Pathogenic. Clinvar id is 91182.Status of the report is reviewed_by_expert_panel, 3 stars. Variant chr2-47412469-CAA-C is described in CliVar as Pathogenic. Clinvar id is 91182.Status of the report is reviewed_by_expert_panel, 3 stars. Variant chr2-47412469-CAA-C is described in CliVar as Pathogenic. Clinvar id is 91182.Status of the report is reviewed_by_expert_panel, 3 stars. Variant chr2-47412469-CAA-C is described in CliVar as Pathogenic. Clinvar id is 91182.Status of the report is reviewed_by_expert_panel, 3 stars. Variant chr2-47412469-CAA-C is described in CliVar as Pathogenic. Clinvar id is 91182.Status of the report is reviewed_by_expert_panel, 3 stars. Variant chr2-47412469-CAA-C is described in CliVar as Pathogenic. Clinvar id is 91182.Status of the report is reviewed_by_expert_panel, 3 stars. Variant chr2-47412469-CAA-C is described in CliVar as Pathogenic. Clinvar id is 91182.Status of the report is reviewed_by_expert_panel, 3 stars. Variant chr2-47412469-CAA-C is described in CliVar as Pathogenic. Clinvar id is 91182.Status of the report is reviewed_by_expert_panel, 3 stars. Variant chr2-47412469-CAA-C is described in CliVar as Pathogenic. Clinvar id is 91182.Status of the report is reviewed_by_expert_panel, 3 stars. Variant chr2-47412469-CAA-C is described in CliVar as Pathogenic. Clinvar id is 91182.Status of the report is reviewed_by_expert_panel, 3 stars. Variant chr2-47412469-CAA-C is described in CliVar as Pathogenic. Clinvar id is 91182.Status of the report is reviewed_by_expert_panel, 3 stars. Variant chr2-47412469-CAA-C is described in CliVar as Pathogenic. Clinvar id is 91182.Status of the report is reviewed_by_expert_panel, 3 stars. Variant chr2-47412469-CAA-C is described in CliVar as Pathogenic. Clinvar id is 91182.Status of the report is reviewed_by_expert_panel, 3 stars. Variant chr2-47412469-CAA-C is described in CliVar as Pathogenic. Clinvar id is 91182.Status of the report is reviewed_by_expert_panel, 3 stars.

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
MSH2NM_000251.3 linkc.704_705delAA p.Lys235ArgfsTer20 frameshift_variant Exon 4 of 16 ENST00000233146.7 NP_000242.1 P43246-1

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
MSH2ENST00000233146.7 linkc.704_705delAA p.Lys235ArgfsTer20 frameshift_variant Exon 4 of 16 1 NM_000251.3 ENSP00000233146.2 P43246-1

Frequencies

GnomAD3 genomes
Cov.:
32
GnomAD2 exomes
AF:
0.00000398
AC:
1
AN:
251348
AF XY:
0.00000736
show subpopulations
Gnomad AFR exome
AF:
0.00
Gnomad AMR exome
AF:
0.00
Gnomad ASJ exome
AF:
0.00
Gnomad EAS exome
AF:
0.00
Gnomad FIN exome
AF:
0.00
Gnomad NFE exome
AF:
0.00000880
Gnomad OTH exome
AF:
0.00
GnomAD4 exome
AF:
0.00000206
AC:
3
AN:
1459814
Hom.:
0
AF XY:
0.00000138
AC XY:
1
AN XY:
726344
show subpopulations
African (AFR)
AF:
0.00
AC:
0
AN:
33422
American (AMR)
AF:
0.00
AC:
0
AN:
44714
Ashkenazi Jewish (ASJ)
AF:
0.00
AC:
0
AN:
26104
East Asian (EAS)
AF:
0.00
AC:
0
AN:
39612
South Asian (SAS)
AF:
0.00
AC:
0
AN:
86204
European-Finnish (FIN)
AF:
0.00
AC:
0
AN:
53368
Middle Eastern (MID)
AF:
0.00
AC:
0
AN:
5766
European-Non Finnish (NFE)
AF:
0.00000180
AC:
2
AN:
1110304
Other (OTH)
AF:
0.0000166
AC:
1
AN:
60320
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.475
Heterozygous variant carriers
0
0
1
1
2
2
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Exome Het
Variant carriers
0
2
4
6
8
10
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome
Cov.:
32

ClinVar

Significance: Pathogenic
Submissions summary: Pathogenic:8
Revision: reviewed by expert panel
LINK: link

Submissions by phenotype

Lynch syndrome Pathogenic:3
Sep 05, 2013
International Society for Gastrointestinal Hereditary Tumours (InSiGHT)
Significance:Pathogenic
Review Status:reviewed by expert panel
Collection Method:research

Coding sequence variation resulting in a stop codon -

Mar 09, 2018
Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine
Significance:Pathogenic
Review Status:criteria provided, single submitter
Collection Method:clinical testing

The p.Lys235fs variant in MSH2 has been reported in 3 individuals with Lynch syn drome-associated cancers (Mangold 2005, Syngal 1999) and been identified in 1/11 1640 European chromosomes by the Genome Aggregation Database (gnomAD, http://gno mad.broadinstitute.org; dbSNP rs281864944). This variant is predicted to cause a frameshift, which alters the protein?s amino acid sequence beginning at positio n 235 and leads to a premature termination codon 20 amino acids downstream. This alteration is then predicted to lead to a truncated or absent protein. Heterozy gous loss of function of the MSH2 gene is an established disease mechanism in in dividuals with Lynch syndrome. In addition, this variant was classified as patho genic on Sep 5, 2013 by the ClinGen-approved InSiGHT expert panel (ClinVar SCV00 0107721.2). In summary, this variant meets criteria to be classified as pathogen ic for Lynch syndrome in an autosomal dominant manner based upon presence in mul tiple affected individuals, low frequency in the general population, and the pre dicted impact on the protein. ACMG/AMP Criteria applied (Richards 2015): PVS1; P M2; PS4_Supporting. -

Apr 20, 2017
Women's Health and Genetics/Laboratory Corporation of America, LabCorp
Significance:Pathogenic
Review Status:criteria provided, single submitter
Collection Method:clinical testing

Variant summary: The MSH2 c.704_705delAA (p.Lys235Argfs) variant results in a premature termination codon, predicted to cause a truncated or absent MSH2 protein due to nonsense mediated decay, which are commonly known mechanisms for disease. Truncations downstream of this position have been classified as pathogenic by our laboratory (e.g. c.1030C>T/ p.Gln344X; c.1147C>T/ p.Arg383X; c.1165C>T/ p.Arg389X; c.1189C>T/ p.Gln397X). In addition, the variant of interest has been reported as pathogenic in multiple affected individuals via publications (Mangold_IJC_2005; Syngal_MLH1_JAMA_1999) and in one reputable database. One in silico tool predicts a damaging outcome for this variant. The variant of interest is absent in a large, broad control population, ExAC in 121020 control chromosomes. Taken together, this variant is classified as pathogenic. -

Hereditary cancer-predisposing syndrome Pathogenic:2
Sep 09, 2024
Ambry Genetics
Significance:Pathogenic
Review Status:criteria provided, single submitter
Collection Method:clinical testing

The c.704_705delAA pathogenic mutation, located in coding exon 4 of the MSH2 gene, results from a deletion of two nucleotides at nucleotide positions 704 to 705, causing a translational frameshift with a predicted alternate stop codon (p.K235Rfs*20). This mutation has been identified in one family fulfilling Amsterdam II criteria (Syngal S et al. JAMA. 1999 Jul;282:247-53), as well as in one individual of German descent fulfilling Bethesda criteria (Mangold E et al. Int. J. Cancer. 2005 Sep;116:692-702). This mutation was also detected in an individual with a family history of urinary tract cancers (Wischhusen JW et al. Cancer Epidemiol Biomarkers Prev, 2020 01;29:193-199). In addition to the clinical data presented in the literature, this alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation. -

Oct 29, 2019
Color Diagnostics, LLC DBA Color Health
Significance:Pathogenic
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This variant deletes 2 nucleotides in exon 4 of the MSH2 gene, creating a frameshift and premature translation stop signal. This variant is expected to result in an absent or non-functional protein product. Splice site prediction tools suggest that this variant may not impact RNA splicing. To our knowledge, functional studies have not been performed for this variant. This variant has been reported in two suspected hereditary nonpolyposis colorectal cancer families (PMID: 10422993, 15849733) and a healthy control from a pancreatic case-control study (PMID: 29922827). This variant has been identified in 1/251348 chromosomes in the general population by the Genome Aggregation Database (gnomAD). Loss of MSH2 function is a known mechanism of disease. Based on the available evidence, this variant is classified as Pathogenic. -

Lynch syndrome 1 Pathogenic:1
Jul 27, 2023
Myriad Genetics, Inc.
Significance:Pathogenic
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This variant is considered pathogenic. This variant creates a frameshift predicted to result in premature protein truncation. -

not provided Pathogenic:1
Aug 01, 2016
GeneDx
Significance:Pathogenic
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This deletion of two nucleotides in MSH2 is denoted c.704_705delAA at the cDNA level and p.Lys235ArgfsX20 (K235RfsX20) at the protein level. The normal sequence, with the bases that are deleted in braces, is ACAA[AA]GACA. The deletion causes a frameshift which changes a Lysine to an Arginine at codon 235, and creates a premature stop codon at position 20 of the new reading frame. This variant is predicted to cause loss of normal protein function through either protein truncation or nonsense-mediated mRNA decay. MSH2 c.704_705delAA has been identified in association with colon cancer (Syngal 1999, Mangold 2005). We consider this variant to be pathogenic. -

Hereditary nonpolyposis colorectal neoplasms Pathogenic:1
Oct 24, 2024
Labcorp Genetics (formerly Invitae), Labcorp
Significance:Pathogenic
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This sequence change creates a premature translational stop signal (p.Lys235Argfs*20) in the MSH2 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in MSH2 are known to be pathogenic (PMID: 15849733, 24362816). This variant is present in population databases (rs281864944, gnomAD 0.0009%). This premature translational stop signal has been observed in individual(s) with Lynch syndrome (PMID: 10422993, 15849733). ClinVar contains an entry for this variant (Variation ID: 91182). For these reasons, this variant has been classified as Pathogenic. -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
PhyloP100
9.0
Mutation Taster
=0/200
disease causing (ClinVar)

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs281864944; hg19: chr2-47639608; API